Study record · Tesamorelin
Tesamorelin for excess abdominal fat in HIV
Visceral adipose tissue decreased about 15.2% with tesamorelin versus an increase of about 5% with placebo.
Key result
Visceral adipose tissue decreased about 15.2% with tesamorelin versus an increase of about 5% with placebo.
Study details
Study designRandomized double-blind placebo-controlled trial
PhasePhase III
PopulationAdults with HIV and excess abdominal fat
Sample size412
RouteSubcutaneous
Regimen / exposure2 mg once daily
Duration26 weeks
ComparatorPlacebo
Primary endpoint / questionVisceral adipose tissue
Safety resultGlucose/IGF-1 monitoring and adverse-event considerations are indication-specific.
Key limitationsStrong evidence for a narrow HIV-associated lipodystrophy indication; not proof of general weight-loss efficacy.
Registry / identifierPMID 18057338